Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2014. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding increases in their ordinary shareholdings.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
There are no material changes to financial performance reported in this document. The only reported activity is the increase in share ownership by specific executives following the re-investment of dividends paid on July 10, 2014.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: July 14, 2014.
- Share Price: 1565.78 pence per share.
- Transaction Type: Re-investment of dividends paid on July 10, 2014.
- Key Participants: Includes Sir Andrew Witty (1,276.962 shares), Mr. S A Hussain (1,619.687 shares), and other senior executives.
- Notification Date: The company was advised of these transactions on July 18, 2014.